Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms

Clinica Chimica Acta

Volumn 404, Issue 2, 2009, Pages 160-165

  Tsai, Shih Meng ^a   Lin, Chiou Ya ^b   Wu, Szu Hsien ^c,d   Hou, Linda Ann ^e   Ma, Hsu ^c,d   Tsai, Li Yu ^b   Hou, Ming Feng ^a  

^a Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^b Department of Medical Laboratory Science and Biotechnology   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ABCB1 polymorphisms; Breast cancer; CYP3A polymorphisms; Docetaxel; Side effects

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE RECEPTOR;

ABCB1 GENE; ADULT; ARTICLE; ASSOCIATION; BREAST CANCER; CYP3A4 GENE; CYP3A5 GENE; DIARRHEA; DRUG FEVER; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GENE; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE NEU; PLEURA EFFUSION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; ETOPOSIDE; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS;

EID: 67349186256     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.03.038     Document Type: Article

References (27)

1. Department of Health, Executive Yuan, ROC: The leading death causes of Taiwan, 2001-2005. URL:http://www.doh.gov.tw/, 2001 2005.
2. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (2005) 5542-5551
3. Estevez L.G., Cuevas J.M., Anton A., et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9 (2003) 686-692
4. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
5. Shou M., Martinet M., Korzekwa K.R., et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8 (1998) 391-401
6. Stearns V., Davidson N.E., and Flockhart D.A. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4 (2004) 143-153
7. Miyoshi Y., Ando A., Takamura Y., et al. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97 (2002) 129-132
8. Tran A., Jullien V., Alexandre J., et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, ABCB1, and GST polymorphisms. Clin Pharmacol Ther 79 (2006) 570-580
9. van Zuylen L., Verweij J., Nooter K., et al. Role of intestinal p-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6 (2000) 2598-2603
10. Hill B.T., Whelan R.D., Shellard S.A., et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12 (1994) 169-182
11. Litman T., Druley T.E., Stein W.D., et al. From MDR, to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58 (2001) 931-959
12. Wang A., Yu B.N., Luo C.H., et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60 (2005) 843-848
13. Ilse P., van der Heiden, van der Werf M., et al. Sequencing: not always the "gold standard". Clin Chem 50 (2004) 248-249
14. Sata F., Sapone A., Elizondo G., et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67 (2000) 48-56
15. Hu Y.F., He J., Chen G.L., et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353 (2005) 187-192
16. Gluck S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10 (2005) 780-791
17. Kelleher M., and Miles D. The adjuvant treatment of breast cancer. Int J Clin Pract 57 (2003) 195-199
18. Garces C.A., and Cance W.G. Neoadjuvant chemotherapy of breast cancer. Am Surg 70 (2004) 565-569
19. Crown J. Docetaxel: overiew of an activedrug for breast cancer. Oncologist 6 suppl 3 (2001) 1-4
20. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-a phase II single-center study. J Clin Oncology 17 (1999) 1127-1131
21. Esposito M., Venturini M., Vannozzi M.O., et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncology 17 (1999) 1132
22. Formm M.F. The influence of ABCB1 polymorphisms on P-glycoprotein expression and function in human. Adv Drug Deliver Rev 54 (2002) 1295-1310
23. Miyoshi Y., Taguchi T., Kim S.J., et al. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 12 (2005) 11-15
24. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 97 (2006) 815-820
25. Brinkmann U., and Eichelbaum M. Polymorphisms in the ABC drug transporter gene ABCB1. Pharmacogenomics J 1 (2001) 59-64
26. Shirakawa K., Takara K., Tanigawara Y., et al. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 90 (1999) 1380-1386
27. Huang M.J., Chen Y.L., Chang C.Y., et al. Polymorphisms of the gene encoding multidrug resistance protein 1 in Taiwanese. J Food Drug Anal 12 (2005) 112-117